Hematologic Oncology

Phase 2 results showed that the investigational monoclonal antibody axatilimab elicited encouraging clinical activity and tolerability across dose levels in patients with recurrent or refractory chronic graft-vs-host disease.

Retrospective, real-world results showed that oral decitabine and cedazuridine and standard parenteral hypomethylating agents demonstrated similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.

Older patients with hematological malignancies who received Orca-T therapy plus myeloablative chemotherapy have similar relapse-free survival rates compared with younger patients.

A virtual care platform significantly reduces hospital days for patients who are receiving CAR T-cell therapy, says Tonya Cox, BSN, RN, OCN.

Six BCMA-directed, CD19-directed autologous CAR T-cell therapies are under investigation for the potential risk of T-cell malignancies.

A recent study published in Nucleus discussed the utility of T-cell replete cord blood transplant in patients with high-risk pediatric acute myeloid leukemia and myelodysplastic syndrome.

A recent study published in Nucleus highlighted the impact of graft-vs-host disease prophylaxis on cytomegalovirus reactivation.

Dose adjustments and alternative treatment regimens may be required amid hematologic drug shortages.

Notch signaling acute gastrointestinal graft-vs-host disease was determined in a study analyzing mice and nonhuman primates.

Julie M. Vose, MD, MBA, reflects on the generic drug shortages and the reasoning behind the continued pattern affecting different cancer types.

Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.

Discrepancies in patients with blood cancer who are eligible for but do not undergo hematopoietic stem cell transplant have been observed not only for Black patients, but Hispanic, Asian, and White patients as well, according to Usama Gergis, MD, MBA.

Nelson J. Chao, MD, MBA, and his colleagues discussed the use of ruxolitinib as treatment for patients with graft-vs-host disease.

Patients with paroxysmal nocturnal hemoglobinuria can now self-administer pegcetacoplan subcutaneously following the FDA’s approval of an injector.

Data from a previous MPN LANDMARK survey highlight that many patients with polycythemia vera experience symptoms that lead to reduced quality of life.

Mohammad Bakri Hammami, MD, highlights a need to address socio-racial disparities among Black and non-Black patients with primary myelofibrosis to ensure that everyone receives high-quality treatment.

Marisol Miranda-Galvis, DDS, MS, PhD, highlights the importance of identifying populations of patients with hematologic cancer who are underserved and using socially targeted solutions.

Panelists share key takeaways on management strategies in myelofibrosis and hope for future evolutions in the treatment paradigm.

Nearing the end of their program, panelists consider a patient with anemic myelofibrosis and optimal treatment strategies in that setting.

In light of the current treatment armamentarium for myelofibrosis, key opinion leaders in the field discuss optimal sequencing of available JAK inhibitors.

Continuing their focus on optimizing JAK inhibitor therapy in myelofibrosis, panelists highlight dosing and adverse event management strategies.

A brief discussion on the role that JAK inhibitors play in cytopenic myelofibrosis and how best to optimize care with sequencing and dose adjustment.

Data from a phase 2 trial support a supplemental new drug application for isavuconazonium sulfate as a treatment for pediatric patients with invasive aspergillosis or invasive mucormycosis.

A broader overview of the role that JAK inhibitors play in patients with myelofibrosis and how that role has continued to evolve in the current treatment paradigm.

Moving on to review the first patient scenario of primary myelofibrosis, panelists elucidate the decisionmaking process when selecting JAK inhibitor therapy.

Expert panelists share brief insight on the current NCCN guidelines for selecting treatment in patients with myelofibrosis.

Focused discussion on the factors that help to select patients for stem cell transplantation over systemic therapy in the setting of myelofibrosis.

Investigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.

The difference in utilizing cytomegalovirus reactivation outcomes while on posttransplantation cyclophosphamide vs other graft-vs-hose disease agents has led to a better understanding in long-term disease and reinfection rates.

A recent study has found that novel graft-versus-leukemia has minor histocompatibility antigens and was all validated.